The work presented here provides support for the strategy of using an SB-based nonviral genetic modification system involving MC transposon donor vectors to simplify the current CAR-T cell production protocol, and these CAR-T cells can be utilized to deliver immune modulatory PD-1 scFv within the tumour microenvironment of HCC. The gene discussed is PDCD1; the disease is neoplasm.